Oncolytic viral therapy is a new promising strategy against cancer. Oncolytic viruses (OVs) can replicate in cancer cells but not in normal cells, leading to lysis of the tumor mass.

Oncolytic Viral Vaccine
Toxicology at CBI
CBI specializes in customizing, designing and implementing GLP toxicology studies for regulatory submission as well as research and non-GLP studies with oncolytic vaccine products for our clients.

Comparative Biosciences, Inc. stays at the forefront of new therapeutics, having conducted numerous toxicology programs with oncolytic viral vaccines for our clients. We, at CBI, are excited to help usher in the next generation of therapies!

HOW CAN CBI AND GD3 SUPPORT YOUR PROGRAMS?

Find out more about GD3, please visit http://gd3services.com/
Contact: Jonathan A. Geller, MS
Business Development Manager
geller@genesisbiotechgroup.com
(888) 994-4870 or (408) 738-9266

NEED TO CONDUCT A STUDY?
Click here and check out our website.
www.compbio.com

Comparative Biosciences, Inc.
786 Lucerne Drive, Sunnyvale, CA 94085 Telephone 408-738-9266